A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Inclusion Criteria:
Kissimmee, Florida 34741, United States
Philadelphia, Pennsylvania 19104, United States
North Terrace, 5000, Australia
Belo Horizonte - MG, 30130-100, Brazil
Montreal, Quebec H1T 2M4, Canada
Ville Mont-Royal, Quebec H3P-3E5, Canada
Guangzhou, 510000, China
Monserrato, 09042, Italy
Shimotsuga-gun, 321-0293, Japan
Shinjuku Ku, 162 8655, Japan
Shinjuku-Ku, 162-8666, Japan
Sumida Ku, 130 8575, Japan
Lørenskog, 1478, Norway
Włocławek, 87-800, Poland